NCT07298824

Clinical Efficacy and Mechanism Exploration of MR-61 in Delaying the Progression of Myopia

Clinical Efficacy and Mechanism Exploration of MR-61 in Delaying the Progression of Myopia: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 164 (estimated)
• Sponsor: Second Affiliated Hospital of Nanchang University · Academic / Other
• Sex: All
• Age: 3 Years – 18 Years
• Healthy volunteers: Not accepted

Summary

To investigate whether probiotic MR-61 can assist in slowing down the progression rate of myopia (a prospective randomized controlled study).

Detailed description

To investigate whether probiotic MR-61 can assist in slowing down the progression rate of myopia (a prospective randomized controlled study).

Conditions

• Myopia Progressing

Interventions

Type	Name	Description
BIOLOGICAL	Investigational Bifidobacterium Preparation MR-61	Oral administration of the investigational probiotic powder MR-61. The primary component is Bifidobacterium. Dosage: one sachet, 2-3 times daily, for 3 months.
OTHER	Placebo for MR-61	Oral administration of a matched placebo powder. Dosage: one sachet, 2-3 times daily, for 3 months.

Timeline

• Start date: 2025-10-01
• Primary completion: 2027-07-01
• Completion: 2027-07-01
• First posted: 2025-12-23
• Last updated: 2025-12-23

Locations

1 site across 1 country: China